Announcement PDF Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222 Neurizon Extends Non-Dilutive R&D Facility to FY2027 and Completes Second Drawdown Highlights: • Research and Development (R&D) financing facility with the Dare Capital Loan Fund extended to cover Neurizon’s FY2027 R&D Rebate • Second drawdown of ~$3.7 million received, secured against the estimated FY2027 R&D Rebate • Total of ~$12.0 million now drawn under this non-dilutive Facility, ahead of receiving any refunds from the ATO • Strategic funding facility allows Neurizon to control the timing of cash earned through its R&D investment, to better match its commitments to the HEALEY ALS Platform Trial • The Facility supported the recent redemption of outstanding Obsidian convertible notes, and complements the recent placement by reducing reliance on other funding sources 13 November 2026 – Melbourne Australia: Neurizon Therapeutics Limited (ASX: NUZ, OTCQB: NUZTF) ("Neurizon" or "the Company") is pleased to announce that it has extended its R&D financing facility with the Dare Capital Loan Fund (the "Facility") to cover its FY2027 R&D Tax Incentive claim (R&D Rebate), and has completed a second drawdown of approximately $3.7 million (refer ASX announcements: 31 July 2026 and 11 August 2026). With an initial drawdown of approximately $8.3 million against the FY2026 R&D Rebate in August 2026, Neurizon has now drawn approximately $12.0 million under the Facility, ahead of receiving any related refund from the Australian Taxation Office. The Facility is non-dilutive. It allows Neurizon to accelerate access to its R&D Rebate entitlement, earned through investment in eligible R&D. As a result of the Advance and Overseas Finding received by Neurizon in September 2025, eligible R&D spend includes, amongst other things, the pivotal Phase 2/3 HEALEY ALS Platform Trial. Rather than waiting for refunds that can only be received after the end of each financial year, the Facility allows the Company to draw funds as eligible expenditure is incurred. The Facility reduces the Company’s reliance on other sources of funding. Together with the recently completed placement, the Facility supported the Company’s redemption of all outstanding convertible notes held by Obsidian and its transition to a simplified funding structure. As Neurizon advances toward the HEALEY topline readout in late Q2 CY2027, it expects to make further drawdowns under the Facility, to ensure the Company retains a cash balance that will support funding flexibility and resilience. The terms of the Facility are otherwise unchanged: interest accrues at 1.25% per month, capitalising monthly, with repayment triggered upon receipt of the relevant R&D Rebate. Chief Executive Officer, Dr Chris Bremer commented: “Extending the Facility to cover FY2027 and completing this second drawdown shows the value of this strategic R&D facility – Neurizon has accessed approximately $12 million of non-dilutive capital before receiving a related refund from the ATO. The Facility gives us control over when we receive the value of our R&D investment, mitigating the need for other, potentially dilutive, sources of funding. I consider the Facility to be an important non-dilutive source of funding that puts Neurizon in a strong position as we head towards the HEALEY ALS Platform Trial topline results in late Q2 CY2027.” -ENDS- This announcement has been authorised for release by the Board of Neurizon Therapeutics Limited. Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222 For further information, please contact: Marketing and Corporate Affairs Lidija Damjanovic Neurizon Therapeutics lidija@neurizon.com +61 (0) 425 700 504 Investor Relations Henry Jordan Six Degrees Investor Relations henry.jordan@sdir.com.au +61 (0) 431 271 538 About Neurizon Therapeutics Limited Neurizon Therapeutics Limited (ASX: NUZ) is a late-clinical stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon’s strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction. Neurizon Investor Hub We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements. To access Neurizon Investor Hub please scan the QR code or visit https://investorhub.neurizon.com Neurizon® is a registered trademark of Neurizon Therapeutics Limited